ASPC

Business Context and Reporting Period

A SPAC III Acquisition Corp. (ASPC) is a blank check company incorporated in the British Virgin Islands, formed to effect a business combination with one or more target businesses, specifically targeting the Environmental, Sustainability and Governance (ESG) and material technology sectors. This Form 10-Q covers the quarter and six months ended June 30, 2026. The Company is currently in the process of consummating a proposed merger with Bioserica International Limited, a developer of bio-based antimicrobial materials.

Key Financial Metrics

Note: The Company has no operating revenue. Interest income is derived solely from the Trust Account.

Material Changes vs. Prior Period

• Net Income to Loss: The Company reported a net loss of $(129,206) for the six months ended June 30, 2026, compared to a net income of $793,141 for the same period in 2025. This shift is primarily due to a significant decrease in interest income earned on the Trust Account ($65,169 in 2026 vs. $1,294,055 in 2025), reflecting lower interest rates and a reduced balance in the Trust Account following massive redemptions in late 2025.
• Trust Account Balance: The Trust Account balance decreased from $2,979,936 at December 31, 2025, to $3,032,747 at June 30, 2026. This follows a major redemption event in October 2025 where 5,717,419 shares were redeemed for approximately $59.5 million, leaving a significantly smaller capital base.
• Share Structure: On January 16, 2026, the Sponsor exchanged 1,499,900 Class B ordinary shares for 1,499,900 Class A ordinary shares. Following this exchange, the Sponsor holds approximately 76.4% of the outstanding Class A shares.
• Operating Expenses: Legal and professional expenses decreased significantly to $101,188 for the six months ended June 30, 2026, compared to $373,666 in the prior year period.

Outlook, Risks, and Contingencies

• Proposed Business Combination: The Company has entered into a Merger Agreement with Bioserica International Limited. The aggregate consideration is valued at $217,860,000, payable in newly issued PubCo shares. The transaction is subject to customary closing conditions.
• Nasdaq Compliance: The Company received notice from Nasdaq on May 20, 2026, regarding non-compliance with the minimum stockholders' equity requirement ($2.5 million). The Company submitted a compliance plan on July 1, 2026, proposing to regain compliance via the Bioserica merger. Nasdaq accepted the plan, granting an extension until November 12, 2026. Failure to regain compliance by this date could result in delisting.
• Going Concern: Management has determined that the mandatory liquidation if a business combination is not completed by November 12, 2026, raises substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include adjustments that might result from this uncertainty.
• Liquidity: The Company has $633,724 in cash outside the Trust Account. While currently sufficient for operations, the Company may need to obtain additional financing to complete the Business Combination or cover working capital deficiencies.

Key Facts for Investor Verification

• Merger Status: Verify the progress of the Bioserica merger and whether all closing conditions are being met prior to the November 12, 2026 deadline.
• Delisting Risk: Confirm the Company's ability to meet Nasdaq's market value or equity requirements by November 12, 2026, to avoid delisting.
• Redemption Exposure: Note that only 282,581 public shares remain subject to redemption (approx. $3.03 million in the Trust), a drastic reduction from the IPO size, significantly altering the capital structure and voting dynamics.
• Sponsor Control: The Sponsor holds approximately 76.4% of the outstanding Class A shares following the share exchange, giving them significant control over the Company's direction.
• Going Concern: Acknowledge the explicit "substantial doubt" regarding the Company's ability to continue as a going concern if the merger fails.